Memorial Hospital Research Laboratories

The Nai-Kong Cheung Lab

Nai-Kong V. Cheung, MD, PhD

Enid A. Haupt Chair in Pediatric Oncology, Pediatrics

My lab focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

View Lab Overview

Featured News

Dr. Nai-Kong V. Cheung, Head, Neuroblastoma Program; Enid A. Haupt Chair in Pediatric Oncology

At Work: Physician-Scientist Nai-Kong Cheung

Meet pediatric oncologist Nai-Kong Cheung, whose research into solid tumors is creating new hope for children with cancer.

Publications Highlights

Santich BH, Cheal SM, Ahmed M, McDevitt MR, Yang G, Ouerfelli Q, Veach DR, Fung EK, Patel M, Vargas DB, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO, Rudin CM, Larson SM, Cheung NK. A Self-Assembling and DisAssembling (SADA) bispecific antibody (BsAb) platform for curative 2-step pre-targeted radioimmunotherapy Clin Can Res, 2020;27(2):532-541. doi:10.1158/1078-0432.CCR-20-2150

Gundem G, Levine MF, Roberts SS, Cheung IY, Medina-Martínez JS, Feng Y, Arango-Ossa JE, Chadoutaud L, Rita M, Asimomitis G, Zhou J, You D, Bouvier N, Spitzer B, Solit DB, Dela Cruz F, LaQuaglia MP, Kushner BH, Modak S, Shukla N, Iacobuzio-Donahue CA, Kung AL, Cheung NV, Papaemmanuil E. Clonal evolution during metastatic spread in high-risk neuroblastoma. Nat Genet. 2023 Jun;55(6):1022-1033. doi: 10.1038/s41588-023-01395-x.

Park JA, Espinosa-Cotton M, Guo HF, Monette S, Cheung NKV. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. J Immunother Cancer 2023 Mar;11(3):e006680. doi:10.1136/jitc-2023-006680.

Chung SK, Vargas DB, Chandler CS, Katugampola S, Veach DR, McDevitt MR, Seo SH, Vaughn BA, Rinne SS, Punzalan B, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Yang G, Ouerfelli O, Nash GM, Cercek A, Fung EK, Howell RW, Larson SM, Cheal SM, Cheung NK. Efficacy of HER2-Targeted Intraperitoneal 225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis. J Nucl Med. 2023 Sep; 64(9):1439-1445. doi: 10.2967/jnumed.122.265095.

Cheung IY, Mauguen A, Modak S, Ragupathi G, Basu EM, Roberts SS, Kushner BH, Cheung NK. Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 Feb;9(2):242-250, doi: 10.1001/jamaoncol.2022.5999

View All Publications

People

Nai-Kong V. Cheung, MD, PhD

Enid A. Haupt Chair in Pediatric Oncology, Pediatrics

Physician-scientist Nai-Kong Cheung focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.
MD, PhD (Immunology), Harvard Medical School

[email protected]: Email Address
646-888-2313: Office Phone
View physician profile: Physician profile

Members

Irene Cheung, ScD — Irene Cheung
Laboratory Member and Attending Clinical Immunologist

Madelyn Espinosa-Cotton
Senior Research Scientist

Hong-fen Guo
Research Assistant/Specialist

Nicole Aguirre

Postdoctoral Fellow

Chih-Ying Lee

Visiting Investigator

Karina Leung

Research Technician

Lab Alumni

Sayed Shahabuddin (Shahab) Hoseini
Research Associate

Tsung-Yi (Steven) Lin, PhD — Tsung-Yi (Steven) Lin
Research Fellow

Alan Long, PhD — Alan Long
Research Scholar

Jeong Park — Jeong A Park
Research Fellow

Mauricio Rendon-Bernot, MD — Mauricio Rendon-Bernot
Clinical Fellow

Brian Santich — Brian H. Santich
Research Fellow

Linlin Wang , PhD — Linlin Wang
Research Associate

Mao (Sally) Wang, PhD — Mao (Sally) Wang
Research Fellow

Yiwei Liu

Senior Research Scientist

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

[email protected]

Lab Head Email
646-888-2313

Office Phone
646-888-2320

Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Nai-Kong V. Cheung discloses the following relationships and financial interests:

Abpro Inc
Equity; Intellectual Property Rights
Biotec Pharmacon
Intellectual Property Rights

Eureka Therapeutics Inc
Equity; Professional Services and Activities
Y-mAbs Therapeutics, Inc.
Equity; Intellectual Property Rights

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures

Changing how the world understands and treats cancer

Training the next generation of clinicians and scientists

We’re here for you.

Make an appointment

Speak to a care advisor

We treat every type of cancer, including the most important one: yours.

Partner with us to treat your patient’s cancer.

CALL OUR DEDICATED CLINICIAN ACCESS NUMBER

Our mission: Ending cancer for life.

In the U.S.

Outside of the U.S.